相关实验视频

Updated: May 4, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

在胃肠道癌症中准NEK基因酶:对基因表达,功能和抑制剂的洞察

Lei Chen¹, Heng Lu^1,2, Farah Ballout¹

¹Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

International journal of molecular sciences

|March 13, 2025

概括

与NIMA相关的激酶 (NEKs),特别是NEK2,在胃肠道癌症中过度表达,导致瘤进展. 用抑制剂向NEK2显示出作为这些难以治疗的恶性瘤的新治疗策略的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

胃肠道 (GI) 癌症是一个重大的全球健康挑战,预后不佳,特别是在晚期.
目前用于肠道癌的治疗方法,包括向和免疫疗法,有效性有限,需要确定新的分子标.
与NIMA相关的激酶 (NEK) 对细胞周期调节至关重要,它们的失调与各种癌症有关.

研究的目的:

审查NEK在肠道癌症中的基因表达和功能作用.
总结开发NEK抑制剂作为肠道恶性瘤治疗策略的进展情况.
突出NEK2作为一个持续过度表达和有前途的目标在所有胃肠道癌症类型.

主要方法:

对肠道癌中NEK基因表达研究的文献综述.
分析NEK在癌症进展和耐药性方面的功能作用.
关于NEK抑制剂的临床前和临床发展的总结.

主要成果:

几位NEK成员在肠道癌症中过度表达,有助于瘤的进展和抵抗.
在所有肠胃癌类型中,NEK2的表达一直过度,这表明它的重要性.
尼克2抑制剂已经显示出有希望的临床前疗效,特别是在胃癌和胰腺癌中.

结论:

NEKs,特别是NEK2,代表了GI癌症治疗的重要分子标.
用特定的抑制剂向NEK2提供了一个有希望的治疗途径,目前正在进行临床试验.
进一步开发和评估NEK抑制剂对于改善肠道癌症治疗结果至关重要.

关键词:

这就是NEK NEK.胃肠道 (GI) 的癌症.基因表达的基因表达方式抑制剂抑制剂抑制剂治疗目标是治疗的目标.

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...